2018
A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53
Mao C, Wang X, Liu Y, Wang M, Yan B, Jiang Y, Shi Y, Shen Y, Liu X, Lai W, Yang R, Xiao D, Cheng Y, Liu S, Zhou H, Cao Y, Yu W, Muegge K, Yu H, Tao Y. A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53. Cancer Research 2018, 78: canres.3454.2017. PMID: 29588351, PMCID: PMC8073197, DOI: 10.1158/0008-5472.can-17-3454.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisBreast NeoplasmsCell Cycle CheckpointsCell NucleusCytoplasmDatasets as TopicDisease ProgressionDNA HelicasesDown-RegulationFemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansKaplan-Meier EstimateLung NeoplasmsMaleMiceMice, NudeMice, SCIDPoly-ADP-Ribose Binding ProteinsProtein BindingRNA HelicasesRNA Recognition MotifRNA Recognition Motif ProteinsRNA, Long NoncodingRNA, Small InterferingSignal TransductionTumor Suppressor Protein p53Xenograft Model Antitumor AssaysConceptsTumor suppressorCancer progressionProtein-binding protein 1Long noncoding RNACell cycle arrestLncRNA functionsRas GTPaseWild-type p53Interaction domainMetabolic genesNoncoding RNAsFunctional domainsP53 modulatorsNucleotides 1P53 pathwayProtein 1Precise roleTypes of cancerLncRNAsSuppressorFerroptosisApoptosisP53ExpressionCfp1
2000
p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer
Angelopoulou K, Yu H, Bharaj B, Giai M, Diamandis E. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clinical Biochemistry 2000, 33: 53-62. PMID: 10693987, DOI: 10.1016/s0009-9120(99)00084-3.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsP53 gene mutationsP53 protein accumulationAntibody-negative patientsP53 antibodiesSeronegative patientsGene mutationsP53 accumulationBreast cancerProportion of patientsPrimary breast cancerFormer patient groupP53 protein overexpressionPatient groupAutoantibody generationProtein accumulationImmune responseSuch antibodiesDirect DNA sequencingCorresponding tumorsPatientsImmunofluorometric assayGene abnormalitiesCancerP53 gene
1999
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
Yu H, Levesque M, Clark G, Diamandis E. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal Of Cancer 1999, 81: 490-495. PMID: 10507775, PMCID: PMC2362935, DOI: 10.1038/sj.bjc.6690720.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkers, TumorBreast NeoplasmsCarcinomaChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDNA ReplicationEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenes, p53HumansLife TablesLymphatic MetastasisMastectomyMultivariate AnalysisNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPloidiesPrognosisProportional Hazards ModelsProstate-Specific AntigenRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneRiskSensitivity and SpecificitySurvival AnalysisSurvival RateTreatment OutcomeTumor Suppressor Protein p53ConceptsEnzyme-linked immunosorbent assayDisease-free survivalBreast cancer patientsCancer patientsRelative riskCox proportional hazards regression analysisProstate-specific antigen expressionProportional hazards regression analysisReceipt of chemotherapyProgesterone receptor statusSteroid hormone receptor analysisHazards regression analysisRecent clinical evidenceLog-rank testKaplan-Meier plotsOverall survival probabilityHormone receptor analysisPrimary breast carcinomaQuantitative enzyme-linked immunosorbent assayProstate-specific antigenP53 expression statusAssessment of p53Breast cancer prognosisS-phase fractionExpression of p53Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou E, Levesque M, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B, Diamandis E. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. Anticancer Research 1999, 19: 749-56. PMID: 10216487.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDNA Mutational AnalysisExonsFemaleFluoroimmunoassayGene ExpressionHumansMiddle AgedMutationOvarian NeoplasmsPolymerase Chain ReactionSequence Analysis, DNATumor Suppressor Protein p53ConceptsP53 protein accumulationOvarian carcinomaP53 abnormalitiesP53 mutationsP53 proteinMissense point mutationsPrimary epithelial ovarian carcinomaEpithelial ovarian carcinomaGrade 3 lesionsCM-1 antibodyP53 protein overexpressionP53 exons 5Exon 5Unfavorable prognosisMutant p53 proteinP53 alterationsSerous histotypeClinical valueStage IIIDO-1Most malignanciesImmunofluorometric assayCarcinomaTumor tissueProtein accumulation
1998
Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients
Levesque M, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, Diamandis E. Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. International Journal Of Cancer 1998, 79: 147-152. PMID: 9583729, DOI: 10.1002/(sici)1097-0215(19980417)79:2<147::aid-ijc9>3.0.co;2-t.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceAntibody SpecificityBreast NeoplasmsCarcinoma, Ductal, BreastCombined Modality TherapyDisease-Free SurvivalFemaleFluorescent Antibody TechniqueHumansLymphatic MetastasisMiddle AgedMultivariate AnalysisNeoplasm StagingPredictive Value of TestsPrognosisReceptors, EstrogenReceptors, ProgesteroneRecurrenceSensitivity and SpecificityTime FactorsTumor Suppressor Protein p53ConceptsP53 proteinItalian breast cancer patientsProgesterone receptor expression statusMultivariate Cox regression analysisP53-negative patientsP53-positive patientsReceptor expression statusDisease-free survivalLymph node statusSteroid hormone receptor analysisCox regression analysisBreast cancer patientsEstrogen receptor expressionHormone receptor analysisCM-1 antibodySensitive immunofluorometric assayBreast cancer prognosisP53 protein accumulationOverall survivalPatient ageIndependent predictorsHistologic typeNode statusPrognostic valueShort patients
1996
Circulating antibodies against p53 protein in patients with ovarian carcinoma
Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis E. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 1996, 78: 2146-2152. PMID: 8918407, DOI: 10.1002/(sici)1097-0142(19961115)78:10<2146::aid-cncr15>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsOvarian carcinomaP53 antibodiesP53 autoantibodiesPositive patientsSuch antibodiesMultivariate analysisPatient disease-free survivalKaplan-Meier survival curvesSerum p53 antibodiesTumor p53 overexpressionDisease-free survivalOlder patient ageSubset of patientsTumor histologic typeOverall patient survivalSera of patientsFrequent molecular eventUnits/LFree survivalNegative patientsOverall survivalPatient ageSuch autoantibodiesAntibody levelsAssociations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer
Yu H, Levesque M, Khosravi M, Papanastasiou-Diamandi A, Clark G, Diamandis E. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. British Journal Of Cancer 1996, 74: 1242-1247. PMID: 8883411, PMCID: PMC2075943, DOI: 10.1038/bjc.1996.523.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorProstate-specific antigenIGFBP-3IGF-IIBreast cancerS-phase fractionIGFBP-1Prognostic indicatorGrowth factorActive insulin-like growth factorsHER-2/neu proteinUnfavourable prognostic indicatorPrimary breast cancerEpidermal growth factor receptorSteroid hormone receptorsTumor tissue cytosolGrowth factor receptorIGF functionEstrogen receptorDNA ploidyPossible associationNeu proteinCancerTissue cytosolsHormone receptors
1995
Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators
Levesque M, Clark G, Yu H, Diamandis E. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. British Journal Of Cancer 1995, 72: 720-727. PMID: 7545416, PMCID: PMC2033897, DOI: 10.1038/bjc.1995.400.Peer-Reviewed Original ResearchConceptsS-phase fractionEpidermal growth factor receptorHER-2/neuProgesterone receptorPrognostic indicatorBreast cancerBreast tumorsProstate-specific antigen expressionIndependent prognostic indicatorP53 proteinProstate-specific antigenAggressive tumor phenotypeWilcoxon rank sum analysisBreast tumor extractsStatus of p53Growth factor receptorPresence of PSARank-sum analysisFavorable prognosisPrognostic factorsBetter prognosisLevels of ERPresence of p53Antigen expressionTumor extractsMutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75: 1327-1338. PMID: 7882283, DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinomaFemaleFluorescent Antibody TechniqueHumansMiddle AgedOvarian NeoplasmsPrognosisProportional Hazards ModelsSurvival AnalysisTumor Suppressor Protein p53ConceptsEpithelial ovarian carcinomaOvarian carcinomaMutant p53 proteinResidual tumorHistologic gradeOvarian cancerP53 proteinCancer relapseMutant p53 protein overexpressionLonger disease-free survivalKaplan-Meier survival curvesPostsurgical residual tumorDisease-free survivalEarly-stage diseaseSubset of patientsLow histologic gradeMutant p53 protein accumulationAdvanced-stage cancerDifferent clinical stagesP53-negative tumorsP53-positive tumorsP53 protein overexpressionPoor patient outcomesAnti-p53 antibodiesP53 protein accumulation
1994
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer
Levesque M, Diamandis E, Yu H, Sutherland D. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Research And Treatment 1994, 30: 179-195. PMID: 7524772, DOI: 10.1007/bf00666062.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigenPrognostic indicatorBreast cancerBreast tumorsBiochemical prognostic indicatorsCandidate prognostic indicatorBreast tumor cytosolsSteroid hormone receptorsNegative associationProgesterone receptorTumor cytosolsMutant p53 proteinTumor extractsP53 tumor suppressor gene productSpecific antigenBiochemical parametersObserved associationsHormone receptorsImmunofluorometric procedureStrong positive associationCognate steroid ligandP53 proteinReceptorsStrong negative associationTumor suppressor gene productDetection of prostate-specific antigen immunoreactivity in breast tumors
Diamandis E, Yu H, Sutherland D. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Research And Treatment 1994, 32: 301-310. PMID: 7532468, DOI: 10.1007/bf00666007.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBreast NeoplasmsFemaleHumansNeoplasm StagingProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneTumor Suppressor Protein p53ConceptsProstate-specific antigenPSA immunoreactivityProgesterone receptorP53 tumor suppressor gene productBreast tumorsProstate-specific antigen immunoreactivitySeminal prostate-specific antigenProgesterone receptor-positive tumorsSensitive immunofluorometric procedureReceptor-positive tumorsEarly disease stagesTumor suppressor gene productBreast tumor extractsSuppressor gene productWestern blot analysisDisease stageProstate carcinomaAntigen immunoreactivityTumor extractsTumor specimensClinical practiceImmunoreactivityTumorsYoung womenImmunofluorometric procedure